diranersen

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.

An experimental Alzheimer's drug, diranersen, developed by Biogen, shows potential to slow cognitive decline by reducing tau protein levels, a key contributor to the disease. Early study results suggest it may offer benefits comparable to existing amyloid-targeting therapies, though further large-scale trials are needed to confirm efficacy.

STAT’s biotech scorecard for Q3 highlights key events for Amylyx Pharmaceuticals and Biogen. Amylyx will report Phase 3 results for avexitide in post-bariatric hypoglycemia, while Biogen will present detailed data from a mid-stage Alzheimer’s trial for diranersen on July 14.

Biogen reported mixed results from a clinical trial for an Alzheimer's disease treatment, while Takeda Pharmaceutical plans to cut about 4,500 jobs as part of a restructuring effort. The Biogen drug, diranersen, reduced levels of tau in patients with early-stage Alzheimer's and slowed cognitive decline. Takeda expects annual savings of over $1.27 billion by fiscal 2028.

Biogen's tau-targeting Alzheimer's drug diranersen showed mixed results in a mid-stage clinical trial, reducing tau levels and slowing cognitive decline, but failed to achieve its primary efficacy goal. The study investigated three escalating dosing regimens, with the lowest dose showing the best results. Biogen reported that tau reductions correlated to a slowing of cognitive decline.